Search

Your search keyword '"Arriola, Edgar' showing total 11 results
Start Over Author "Arriola, Edgar Language english
11 results on '"Arriola, Edgar'

1. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Author

Tashkin, Donald P, Roth, Michael D, Clements, Philip J, Furst, Daniel E, Khanna, Dinesh, Kleerup, Eric C, Goldin, Jonathan, Arriola, Edgar, Volkmann, Elizabeth R, Kafaja, Suzanne, Silver, Richard, Steen, Virginia, Strange, Charlie, Wise, Robert, Wigley, Fredrick, Mayes, Maureen, Riley, David J, Hussain, Sabiha, Assassi, Shervin, Hsu, Vivien M, Patel, Bela, Phillips, Kristine, Martinez, Fernando, Golden, Jeffrey, Connolly, M Kari, Varga, John, Dematte, Jane, Hinchcliff, Monique E, Fischer, Aryeh, Swigris, Jeffrey, Meehan, Richard, Theodore, Arthur, Simms, Robert, Volkov, Suncica, Schraufnagel, Dean E, Scholand, Mary Beth, Frech, Tracy, Molitor, Jerry A, Highland, Kristin, Read, Charles A, Fritzler, Marvin J, Kim, Grace Hyun J, Tseng, Chi-Hong, and Elashoff, Robert M

Published
2016
Full Text
View/download PDF

2. Cyclophosphamide versus placebo in scleroderma lung disease

Author

Tashkin, Donald P.; Elashoff, Robert; Clements, Philip J.; Goldin, Jonathan; Roth, Michael D.; Furst, Daniel E., Arriola, Edgar; Silver, Richard; Strange, Charlie; Bolster, Marcy; Seibold, James R., Riley, David J.; Hsu, Vivien M.; Varga, John; Schraufnagel, Dean E., Theodore, Arthur; Simms, Robert; Wise, Robert; Wigley, Fredrick; White, Barbara; Steen, Virginia; Read, Charles; Mayes, Maureen; Parsley, Ed D.O.; Mubarak, Kamal, and Connolly, Kari; Golden, Jeffrey; Olman, Mitchell; Fessler, Barri; Rothfield, Naomi; Metersky, Mark

Subjects
Scleroderma (Disease) -- Drug therapy, Systemic scleroderma -- Drug therapy, Lung diseases -- Drug therapy, Quality of life
Abstract

A double-blind, randomized, placebo-controlled trial was conducted to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related interstitial lung disease. It was found that one year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.

Published
2006

3. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Author

Tashkin, Donald P., Elashoff, Robert, Clements, Philip J., Roth, Michael D., Furst, Daniel E., Silver, Richard M., Goldin, Jonathan, Arriola, Edgar, Strange, Charlie, Bolster, Marcy B., Seibold, James R., Riley, David J., Hsu, Vivien M., Varga, John, Schraufnagel, Dean, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fred, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, Kari M., Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark, Khanna, Dinesh, Li, Ning, and Li, Gang

Published
2007
Full Text
View/download PDF

4. The menopause

Author

Greendale, Gail A, Lee, Nancy P, and Arriola, Edgar R

Published
1999

5. Mycophenolate Mofetil

Author

Sievers, Theodore M., Rossi, Stephen J., Ghobrial, Rafik M., Arriola, Edgar, Nishimura, Pamela, Kawano, Marv, and Holt, Curtis D.

Published
1997

6. Topical corticosteroids: back to basics

Author

Lee, Nancy P. and Arriola, Edgar R.

Subjects
Dosage and administration, Health aspects, Adrenocortical hormones -- Dosage and administration -- Health aspects, Topical drugs -- Health aspects -- Dosage and administration, Topical medication -- Health aspects -- Dosage and administration
Abstract

Topical corticosteroids are among the most commonly prescribed medications in the ambulatory setting.[1] They are the cornerstones of therapy for a wide variety of dermatoses, such as atopic dermatitis, contact [...]

Published
1999

7. Poison ivy, oak, and sumac dermatitis

Author

Lee, Nancy P. and Arriola, Edgar R.

Subjects
Health aspects, Causes of, Poison oak -- Health aspects, Toxicodendron -- Health aspects, Poison ivy -- Health aspects, Contact dermatitis -- Causes of -- Health aspects, Poison-ivy -- Health aspects
Abstract

The main causes of allergic contact dermatitis in the United States include four commonly encountered species of the Anacardiaceae family: poison ivy (Toxicodendron radicans) (Figure 1) western poison oak (Toxicodendron [...]

Published
1999

8. How to treat allergic rhinitis

Author

Lee, Nancy P. and Arriola, Edgar R.

Subjects
Care and treatment, Hay fever -- Care and treatment, Hay-fever -- Care and treatment
Abstract

INTRODUCTION Allergic rhinitis is an IgE-mediated inflammatory disease of the nasal mucosal membranes characterized mainly by sneezing, rhinorrhea, nasal pruritis, and congestion. It is the most common form of rhinitis, [...]

Published
1999

9. Treatment advances in rheumatoid arthritis

Author

Arriola, Edgar R. and Lee, Nancy P.

Subjects
Arava (Medication) -- Health aspects, Enbrel (Medication) -- Health aspects, Celebrex (Medication) -- Health aspects, Drug therapy, Health aspects, Rheumatoid arthritis -- Drug therapy, Leflunomide -- Health aspects
Abstract

Rheumatoid arthritis (RA) is a chronic, often debilitating autoimmune disorder characterized by persistent synovial inflammation that leads to cartilage and bone destruction. RA afflicts over 2 million Americans and contributes [...]

Published
1999

10. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Author

Edgar Arriola, Marcy B. Bolster, John Varga, Robert Elashoff, Gang Li, Maureen D. Mayes, Charlie Strange, Donald P. Tashkin, Dinesh Khanna, Naomi F. Rothfield, Dean E. Schraufnagel, Vivien Hsu, Ed Parsley, Fred M. Wigley, Jonathan G. Goldin, Mark L. Metersky, Robert A. Wise, Ning Li, Barbara White, James R. Seibold, Barri J. Fessler, Daniel E. Furst, Jeffrey A. Golden, Virginia D. Steen, Mitchell A. Olman, Michael D. Roth, M. Kari Connolly, David J. Riley, Charles A. Read, Richard M. Silver, Kamal K. Mubarak, Arthur C. Theodore, Robert W. Simms, and Philip J. Clements

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Time Factors, Pulmonary Fibrosis, Administration, Oral, Critical Care and Intensive Care Medicine, Placebo, Scleroderma, Drug Administration Schedule, Pulmonary function testing, FEV1/FVC ratio, Internal medicine, Intensive care, Pulmonary fibrosis, Medicine, Humans, Lung volumes, Cyclophosphamide, Scleroderma, Systemic, integumentary system, business.industry, Total Lung Capacity, E. Interstitial Lung Disease, Interstitial lung disease, Middle Aged, medicine.disease, Surgery, Treatment Outcome, Female, business, Immunosuppressive Agents, Follow-Up Studies
Abstract

The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear.A second year of follow-up was performed to determine if these effects persisted after stopping treatment.A detailed analysis of data obtained over the two years of the study was performed.Using a longitudinal joint model, we analyzed FVC, total lung capacity, transitional dyspnea index, Rodnan skin scores, and the Health Assessment Questionnaire-Disability Index during the second year, after adjusting for baseline values, baseline fibrosis score, and nonignorable missing data. Evaluable subjects (72 CYC; 73 placebo) included 93 who completed all visits plus 52 who completed at least 6 months of therapy and returned at 24 month or had their 24-month data imputed. The beneficial effects of CYC on pulmonary function and health status continued to increase through 18 months, after which they dissipated, whereas skin improvements dissipated after 12 months. In contrast, the positive effect on dyspnea persisted through 24 months. Adverse events were uncommon.One year of CYC improved lung function, skin scores, dyspnea, and health status/disability, effects which either persisted or increased further for several months after stopping therapy. However, except for a sustained impact on dyspnea, all of these effects waned and were no longer apparent at 24 months. Treatment strategies aimed at extending the positive therapeutic effects observed with CYC should be considered. Clinical trial registered with www.clinicaltrials.gov (NCT 000004563).

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results